NU2058 - CAS 161058-83-9
Catalog number: 161058-83-9
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
Molecular Weight:
NU2058 is a potent CDK inhibitor. which has CDK2 IC(50)=17 microM and CDK1 IC(50)=26 microM.
NU2058; NU 2058; NU-2058; O(6)-Cyclohexylmethylguanine.
Canonical SMILES:
1.Searching for cyclin-dependent kinase inhibitors using a new variant of the cope elimination.
Griffin RJ;Henderson A;Curtin NJ;Echalier A;Endicott JA;Hardcastle IR;Newell DR;Noble ME;Wang LZ;Golding BT J Am Chem Soc. 2006 May 10;128(18):6012-3.
beta-Piperidinoethylsulfides are oxidized by m-chloroperbenzoic acid to intermediates containing both N-oxide and sulfone functions. These undergo a Cope-type elimination to a vinylsulfone that can be captured by amines to afford beta-aminoethylsulfones. When a beta-aminoethylsulfone group is linked to the 4-position of a phenyl group attached at N-2 of O6-cyclohexylmethylguanine, the resulting derivatives are inhibitors of the cyclin-dependent kinase CDK2. One of the most potent inhibitors (IC50 = 45 nM) contained a N-3-hydroxypropyl group on the aminoethylsulfonyl substituent. The crystal structure of this inhibitor bound to CDK2/cyclin A was determined and shows an unusual network of hydrogen bonds. The synthetic methodology developed can be utilized in multiple-parallel format and has numerous potential applications in medicinal chemistry.
2.EmbR2, a structural homologue of EmbR, inhibits the Mycobacterium tuberculosis kinase/substrate pair PknH/EmbR.
Molle V;Reynolds RC;Alderwick LJ;Besra GS;Cozzone AJ;Fütterer K;Kremer L Biochem J. 2008 Mar 1;410(2):309-17.
EmbR is a transcriptional regulator that is phosphorylated by the cognate mycobacterial STPK (serine/threonine protein kinase) PknH. Recent studies demonstrated that PknH-dependent phosphorylation of EmbR enhances its DNA-binding activity and activates the transcription of the embCAB genes encoding arabinosyltransferases, which participate in arabinan biosynthesis. In the present study, we identified a genomic region of 4425 bp, which is present in Mycobacterium tuberculosis CDC1551, but absent from M. tuberculosis H37Rv, comprising the MT3428 gene, which is homologous with embR. Homology modelling of the MT3428 gene product illustrated its close relationship (56% identity) to EmbR, and it was hence termed EmbR2. In marked contrast with EmbR, EmbR2 was not phosphorylated by PknH, although it is a substrate of other M. tuberculosis kinases, including PknE and PknF. Tryptophan fluorescence emission of EmbR2 was monitored in the presence of three different PknH-derived phosphopeptides and demonstrated that EmbR2 binds to at least two of the threonine sites known to undergo autophosphorylation in PknH. We observed that the capacity of EmbR2 to interact physically with PknH without being phosphorylated was a result of EmbR2-mediated inhibition of kinase activity: incubation of PknH with increasing concentrations of EmbR2 led to a dose-response inhibition of the autokinase activity, similarly to O6-cyclohexylmethylguanine, a known inhibitor of eukaryotic cyclin-dependent kinases.
3.Therapeutic potential of CDK inhibitor NU2058 in androgen-independent prostate cancer.
Rigas AC;Robson CN;Curtin NJ Oncogene. 2007 Dec 6;26(55):7611-9. Epub 2007 Jun 18.
Antiandrogens are initially effective in controlling prostate cancer (CaP), the second most common cancer in men, but resistance, associated with the loss of androgen-regulated cell cycle control, is a major problem. At present there is no effective treatment for androgen-independent prostate cancer (AIPC). Cellular proliferation is driven by cyclin-dependent kinases (CDKs) with kinase inhibitors (for example, p27) applying the breaks. We present the first investigation of the therapeutic potential of CDK inhibitors, using the guanine-based CDK inhibitor NU2058 (CDK2 IC(50)=17 microM, CDK1 IC(50)=26 microM), in comparison with the antiandrogen bicalutamide (Casodex) in AIPC cells. A panel of AIPC cells was found to be resistant to Casodex-induced growth inhibition, but with the exception of PC3 (GI(50)=38 microM) and CWR22Rv1 (GI(50)=46 microM) showed similar sensitivity to NU2058 (GI(50)=10-17 microM) compared to androgen-sensitive LNCaP cells (GI(50)=15 microM). In LNCaP cells and their Casodex-resistant derivative, LNCaP-cdxR, growth inhibition by NU2058 was accompanied by a concentration-dependent increase in p27 levels, reduced CDK2 activity and pRb phosphorylation, a decrease in early gene expression and G1 cell cycle phase arrest in both cell lines.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related CDK Products

CAS 161058-83-9 NU2058

(CAS: 161058-83-9)

NU2058 is a potent CDK inhibitor. which has CDK2 IC(50)=17 microM and CDK1 IC(50)=26 microM.

CAS 1231929-97-7 Abemaciclib

(CAS: 1231929-97-7)

Abemaciclib is an orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with poten...

CAS 1414943-88-6 BAY-1143572

(CAS: 1414943-88-6)

BAY 1143572 is a highly selective, potent and orally available inhibitor ofPTEFb/CDK9 and shows convincing anti-tumor activity in multiple xenograft models by t...

CAS 1211443-80-9 LEE011 hydrochloride

LEE011 hydrochloride
(CAS: 1211443-80-9)

CDK4/6 inhibitor LEE011 specifically inhibits CDK4 and 6, thereby inhibiting retinoblastoma (Rb) protein phosphorylation. Inhibition of Rb phosphorylation preve...

CAS 571190-30-2 Palbociclib

(CAS: 571190-30-2)

Palbociclib is an orally available cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. Palbociclib selectively inhibits cyclin-depen...

CAS 1453834-21-3 LDC4297

(CAS: 1453834-21-3)

LDC4297 is a potent and selective cyclin-dependent protein kinase 7 (CDK7) inhibitor with an IC50 of 0.13 nM.

CAS 186692-46-6 Seliciclib

(CAS: 186692-46-6)

Seliciclib is an orally bioavailable, small-molecule cyclin-dependent kinase (CDK) inhibitor with potential proapoptotic and antineoplastic activities. Selicicl...

(CAS: 1229665-91-1)

CGP-79807 is a potent CDC2 protein kinase inhibitor that originated by Novartis. In Sep 2000, Preclinical development for Cancer in Switzerland was on-going, bu...

Chemical Structure

CAS 161058-83-9 NU2058

Quick Inquiry

Verification code

Featured Items